Shire plc announces that its partner in Japan, Shionogi & Co., Ltd has submitted a New Drug Application (NDA) for the manufacture and marketing in Japan of INTUNIV ® for the treatment of attention deficit hyperactivity disorder (ADHD) in adults. The Japanese Phase 3 clinical trial was the first ever to evaluate INTUNIV in adult patients (18 years and over) with ADHD. INTUNIV, a non-stimulant, selective alpha-2A adrenergic receptor agonist has been approved as a treatment for child and adolescent patients (6 to 17 years old) with ADHD in Japan since March 2017. INTUNIV is being co-developed and commercialised by Shire and Shionogi under a licensing contract signed in 2011. ADHD is characterised by 3 core symptoms of inattention, hyperactivity or impulsivity, or a combination of these symptoms, and can have substantial impact on major areas of life, including: schooling, work and employment, behaviour, and social functioning.